Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$10.8 million.

  • Compass Therapeutics' Cash from Operations rose 182.79% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 623.56%. This contributed to the annual value of -$44.9 million for FY2024, which is 1043.13% down from last year.
  • Compass Therapeutics' Cash from Operations amounted to -$10.8 million in Q3 2025, which was up 182.79% from -$11.8 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Cash from Operations high stood at -$5.9 million for Q3 2023, and its period low was -$13.9 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$11.1 million (2024), whereas its average is -$11.0 million.
  • Over the last 5 years, Compass Therapeutics' Cash from Operations had its largest YoY gain of 2583.78% in 2024, and its largest YoY loss of 8660.93% in 2024.
  • Compass Therapeutics' Cash from Operations (Quarter) stood at -$12.4 million in 2023, then rose by 25.84% to -$9.2 million in 2024, then dropped by 18.41% to -$10.8 million in 2025.
  • Its last three reported values are -$10.8 million in Q3 2025, -$11.8 million for Q2 2025, and -$13.2 million during Q1 2025.